Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8N201
UPID:
INT1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N201; A6NJ44; Q6NT70; Q6UX74; Q8WV40; Q96D36; Q9NTD1; Q9P2A8; Q9Y3W8
Background:
Integrator complex subunit 1 plays a pivotal role in the transcription and processing of small nuclear RNAs (snRNA), essential for pre-mRNA splicing. It is a key component of the Integrator complex, associated with RNA polymerase II, facilitating the recruitment of cytoplasmic dynein to the nuclear envelope.
Therapeutic significance:
Linked to a neurodevelopmental disorder characterized by developmental delays, dysmorphic facies, and cataracts, Integrator complex subunit 1's understanding could pave the way for novel therapeutic approaches.